Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.24.1.1.u2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Jun. 30, 2023
Current assets:    
Cash and cash equivalents $ 5,930 $ 16,036
Investments in marketable debt securities 74,092 85,860
Prepaid expenses and other 2,188 3,014
Total current assets 82,210 104,910
Long-term assets:    
Investments in marketable debt securities 1,573 16,470
Right-of-use assets 2,006 2,054
Property and equipment, net 110 139
Deposits and other 1,838 148
Total assets 87,737 123,721
Current liabilities:    
Accounts payable 3,499 3,269
Accrued liabilities:    
Accrued clinical and other 2,027 507
Compensation and benefits 879 883
Current portion of operating lease liabilities 552 541
Total current liabilities 6,957 5,200
Long term liabilities:    
Operating lease liabilities, net of current portion 1,819 1,937
Warrant derivative liability 7,647  
Embedded derivative liability 453 412
Total liabilities 16,876 7,549
Commitments and contingencies (Notes 5, 9 and 10)
Shareholders' equity:    
Preferred stock, $0.001 par value; 400 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 100,000 shares authorized; issued and outstanding 40,132 and 36,827 shares as of March 31, 2024 and June 30, 2023, respectively 40 37
Additional paid-in capital 377,367 377,471
Accumulated other comprehensive loss (78) (351)
Accumulated deficit (306,468) (260,985)
Total shareholders' equity 70,861 116,172
Total liabilities and shareholders' equity $ 87,737 $ 123,721